UNSPSC 51101629: Trimetrexate

This classification denotes a folate antagonist and dihydrofolate reductase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UPN4ITI8T4. European Medicines Agency schedules Trimetrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11312MIG. Trimetrexate generally arises in the molecular formula C19H23N5O3. The term TRIMETREXATE is an International Non-Proprietary Name or INN.

UNSPSC 51101629 Trimetrexate, a Commodity code, nominally covers a specific pharmaceutical product; however, recent state and local opportunities tagged under this code show minimal alignment with the code's narrow scope. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride — neither of which is trimetrexate — and Seminole County, Florida released a separate procurement for Naloxone and Safe Drug Deactivation Systems, also unrelated to the code's stated product. When state and local procurement offices tag opportunities under this code, they appear to be using it as a catch-all for pharmaceutical supply chain activity rather than sourcing trimetrexate specifically. The issuing bodies active under this code include state health departments and county government, particularly health and emergency-management functions.

Recent activity spans Illinois and Florida, though the two recorded opportunities are awards or past-due solicitations rather than open opportunities currently accepting bids. The Illinois award to Chartwell Rx LLC closed August 28, 2026, for a $2,999,999.11 three-year pharmaceutical supply contract through competitive bidding. Seminole County's Naloxone and drug-deactivation procurement carried a July 26, 2023 deadline—well outside the current window—and required quarterly deliveries to the county's community health building in Sanford. The code shows little current open-market activity relevant to trimetrexate procurement itself, signaling either very light state and local demand for this specific drug or persistent classification misalignment in procurement systems.